The Journal of Bone and Joint Surgery (American). 2009;91:634-641.
doi:10.2106/JBJS.G.01029
© 2009 The Journal of Bone and Joint Surgery, Inc.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME: Take the activities for this article:
 Adult Hip Reconstruction Test 32: Spring 2009 (publication date May 15, 200...
CME 1: January, February, March 2009 (publication date April 3, 2009; expir...
Right arrow [Supplementary Material]
Right arrow Letters to the Editor: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Letters to the Editor are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cummins, J. S.
Right arrow Articles by Finlayson, S. R.G.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Cummins, J. S.
Right arrow Articles by Finlayson, S. R.G.
Related Collections
Right arrow Adult Hip
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Facebook   Add to Technorati   Add to Twitter  
What's this?

Cost-Effectiveness of Antibiotic-Impregnated Bone Cement Used in Primary Total Hip Arthroplasty

Justin S. Cummins, MD, MS1, Ivan M. Tomek, MD1, Stephen R. Kantor, MD1, Ove Furnes, MD, PhD2, Lars Birger Engesæter, MD, PhD2 and Samuel R.G. Finlayson, MD, MPH1

1 Departments of Orthopaedic Surgery (J.S.C., I.M.T., and S.R.K.) and Surgery (S.R.G.F.), Dartmouth Hitchcock Medical Center, One Medical Center Drive, Lebanon, NH 03756. E-mail address for J.S. Cummins: jcummins.md{at}gmail.com
2 Department of Orthopaedic Surgery, Haukeland University Hospital, N-5021 Bergen, Norway

Investigation performed at the Department of Orthopaedic Surgery, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire

Disclosure: The authors did not receive any outside funding or grants in support of their research for or preparation of this work. Neither they nor a member of their immediate families received payments or other benefits or a commitment or agreement to provide such benefits from a commercial entity. No commercial entity paid or directed, or agreed to pay or direct, any benefits to any research fund, foundation, division, center, clinical practice, or other charitable or nonprofit organization with which the authors, or a member of their immediate families, are affiliated or associated.

A commentary is available with the electronic versions of this article, on our web site (www.jbjs.org) and on our quarterly CD-ROM/DVD (call our subscription department, at 781-449-9780, to order the CD-ROM or DVD).

Background: Antibiotic-impregnated bone cement is infrequently used in the United States for primary total hip arthroplasty because of concerns about cost, performance, and the possible development of antibiotic resistance and because it has been approved only for use in revision arthroplasty after infection. The purpose of this study was to model the use of antibiotic-impregnated bone cement in primary total hip arthroplasty for the treatment of osteoarthritis to determine whether use of the cement is cost-effective when compared with the use of cement without antibiotics.

Methods: To evaluate the cost-effectiveness of each strategy, we used a Markov decision model to tabulate costs and quality-adjusted life years (QALYs) accumulated by each patient. Rates of revision due to infection and aseptic loosening were estimated from data in the Norwegian Arthroplasty Register and were used to determine the probability of undergoing a revision arthroplasty because of either infection or aseptic loosening. The primary outcome measure was either all revisions or revision due to infection. Perioperative mortality rates, utilities, and disutilities were estimated from data in the arthroplasty literature. Costs for primary arthroplasty were estimated from data on in-hospital resource use in the literature. The additional cost of using antibiotic-impregnated bone cement ($600) was then added to the average cost of the initial procedure ($21,654).

Results: When all revisions were considered to be the primary outcome measure, the use of antibiotic-impregnated bone cement was found to result in a decrease in overall cost of $200 per patient. When revision due to infection was considered to be the primary outcome measure, the use of the cement was found to have an incremental cost-effectiveness ratio of $37,355 per QALY compared with cement without antibiotics; this cost-effectiveness compares favorably with that of accepted medical procedures. When only revision due to infection was considered, it was found that the additional cost of the antibiotic-impregnated bone cement would need to exceed $650 or the average patient age would need to be greater than seventy-one years before its cost would exceed $50,000 per QALY gained.

Conclusions: When revision due to either infection or aseptic loosening is considered to be the primary outcome, the use of antibiotic-impregnated bone cement results in an overall cost decrease. When only revision due to infection is considered, the model is strongly influenced by the cost of the cement and the average age of the patients. With few patients less than seventy years of age undergoing total hip arthroplasty with cement in the United States, the use of antibiotic-impregnated bone cement in primary total hip arthroplasty may be of limited value unless its cost is substantially reduced.

Level of Evidence: Economic and decision analysis, Level II. See Instructions to Authors for a complete description of levels of evidence.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Facebook Facebook   Add to Technorati Technorati   Add to Twitter Twitter    What's this?